Skip to main content
Top
Published in: Digestive Diseases and Sciences 12/2021

01-12-2021 | Hepatic Encephalopathy | Original Article

Comparison of Seven Noninvasive Models for Predicting Decompensation and Hospitalization in Patients with Cirrhosis

Authors: Chia-Yang Hsu, Neehar D. Parikh, Teh-Ia Huo, Elliot B. Tapper

Published in: Digestive Diseases and Sciences | Issue 12/2021

Login to get access

Abstract

Background/Aim

Patients with cirrhosis have poor outcomes once decompensation occurs; however, we lack adequate predictors of decompensation. To use a national claim database to compare the predictive accuracy of seven models for decompensation and hospitalization in patients with compensated cirrhosis.

Methods

We defined decompensation as ascites, hepatic encephalopathy, hepato-renal syndrome, and variceal bleeding. Patients without decompensation at the time of cirrhosis diagnosis were enrolled from 2001 to 2015. Patients with hepatitis B and/or C were grouped as viral cirrhosis. We compared the predictive accuracy of models with the AUC (area under the curve) and c-statistic. The cumulative incidence of decompensation and incidence risk ratios of hospitalization were calculated with the Fine–Gray competing risk and negative binomial models, respectively.

Results

A total of 3722 unique patients were enrolled with a mean follow-up time of 524 days. The mean age was 59 (standard deviation 12), and the majority were male (55%) and white (65%). Fifty-three percent of patients had non-viral cirrhosis. Sixteen and 20 percent of patients with non-viral and viral cirrhosis, respectively, developed decompensation (P = 0.589). The FIB-4 model had the highest 3-year AUC (0.73) and overall c-statistic (0.692) in patients with non-viral cirrhosis. The ALBI-FIB-4 model had the best 1-year (AUC = 0.741), 3-year (AUC = 0.754), and overall predictive accuracy (c-statistic = 0.681) in patients with viral cirrhosis. The MELD score had the best predictive power for hospitalization in both non-viral and viral patients.

Conclusions

FIB-4-based models provide more accurate prediction for decompensation, and the MELD model has the best predictive ability of hospitalization.
Appendix
Available only for authorised users
Literature
1.
go back to reference D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–231.CrossRef D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–231.CrossRef
2.
go back to reference D’Amico G, Morabito A, D’Amico M, et al. New concepts on the clinical course and stratification of compensated and decompensated cirrhosis. Hepatol Int.. 2018;12:34–43.CrossRef D’Amico G, Morabito A, D’Amico M, et al. New concepts on the clinical course and stratification of compensated and decompensated cirrhosis. Hepatol Int.. 2018;12:34–43.CrossRef
3.
go back to reference Tapper EB, Zhang P, Garg R, et al. Body composition predicts mortality and decompensation in compensated cirrhosis patients: A prospective cohort study. JHEP Rep.. 2020;2:100061.CrossRef Tapper EB, Zhang P, Garg R, et al. Body composition predicts mortality and decompensation in compensated cirrhosis patients: A prospective cohort study. JHEP Rep.. 2020;2:100061.CrossRef
4.
go back to reference Guha IN, Harris R, Berhane S, et al. Validation of a model for identification of patients with compensated cirrhosis at high risk of decompensation. Clin Gastroenterol Hepatol.. 2019;17:e1.CrossRef Guha IN, Harris R, Berhane S, et al. Validation of a model for identification of patients with compensated cirrhosis at high risk of decompensation. Clin Gastroenterol Hepatol.. 2019;17:e1.CrossRef
5.
go back to reference Hung TH, Hsieh MH, Lay CJ, et al. Increased occurrence of native septic arthritis in adult cirrhotic patients: a population-based three-year follow-up study in Taiwan. Prz Gastroenterol.. 2014;9:342–347.CrossRef Hung TH, Hsieh MH, Lay CJ, et al. Increased occurrence of native septic arthritis in adult cirrhotic patients: a population-based three-year follow-up study in Taiwan. Prz Gastroenterol.. 2014;9:342–347.CrossRef
6.
go back to reference Hung TH, Hsieh YH, Tseng KC, et al. The risk for bacterial endocarditis in cirrhotic patients: a population-based 3-year follow-up study. Int J Infect Dis.. 2013;17:e391.CrossRef Hung TH, Hsieh YH, Tseng KC, et al. The risk for bacterial endocarditis in cirrhotic patients: a population-based 3-year follow-up study. Int J Infect Dis.. 2013;17:e391.CrossRef
7.
go back to reference Parikh NS, Kamel H, Navi BB, et al. Liver fibrosis indices and outcomes after primary intracerebral hemorrhage. Stroke. 2020:STROKEAHA119028161. Parikh NS, Kamel H, Navi BB, et al. Liver fibrosis indices and outcomes after primary intracerebral hemorrhage. Stroke. 2020:STROKEAHA119028161.
8.
go back to reference Mittal VS, Wu B, Song J, et al. Healthcare resource utilization and costs among nonvalvular atrial fibrillation patients initiating rivaroxaban or warfarin in skilled nursing facilities: a retrospective cohort study. Curr Med Res Opin.. 2019;20:1. Mittal VS, Wu B, Song J, et al. Healthcare resource utilization and costs among nonvalvular atrial fibrillation patients initiating rivaroxaban or warfarin in skilled nursing facilities: a retrospective cohort study. Curr Med Res Opin.. 2019;20:1.
9.
go back to reference Allen AM, Therneau TM, Larson JJ, et al. Nonalcoholic fatty liver disease incidence and impact on metabotlic burden and death: a 20 year-community study. Hepatology.. 2018;67:1726–1736.CrossRef Allen AM, Therneau TM, Larson JJ, et al. Nonalcoholic fatty liver disease incidence and impact on metabotlic burden and death: a 20 year-community study. Hepatology.. 2018;67:1726–1736.CrossRef
10.
go back to reference Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med.. 2017;36:4391–4400.CrossRef Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med.. 2017;36:4391–4400.CrossRef
11.
go back to reference Uno H, Cai T, Pencina MJ, et al. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med.. 2011;30:1105–1117.CrossRef Uno H, Cai T, Pencina MJ, et al. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med.. 2011;30:1105–1117.CrossRef
12.
go back to reference Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol.. 2006;4:1385–1394.CrossRef Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol.. 2006;4:1385–1394.CrossRef
13.
go back to reference D’Amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther.. 2014;39:1180–1193.CrossRef D’Amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther.. 2014;39:1180–1193.CrossRef
14.
go back to reference Chen RC, Cai YJ, Wu JM, et al. Usefulness of albumin-bilirubin grade for evaluation of long-term prognosis for hepatitis B-related cirrhosis. J Viral Hepat.. 2017;24:238–245.CrossRef Chen RC, Cai YJ, Wu JM, et al. Usefulness of albumin-bilirubin grade for evaluation of long-term prognosis for hepatitis B-related cirrhosis. J Viral Hepat.. 2017;24:238–245.CrossRef
15.
go back to reference Angulo P, Bugianesi E, Bjornsson ES, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology.. 2013;145:e4.CrossRef Angulo P, Bugianesi E, Bjornsson ES, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology.. 2013;145:e4.CrossRef
16.
go back to reference Chen B, Lin S. Albumin-bilirubin (ALBI) score at admission predicts possible outcomes in patients with acute-on-chronic liver failure. Medicine (Baltimore).. 2017;96:e7142.CrossRef Chen B, Lin S. Albumin-bilirubin (ALBI) score at admission predicts possible outcomes in patients with acute-on-chronic liver failure. Medicine (Baltimore).. 2017;96:e7142.CrossRef
17.
go back to reference Wang J, Zhang Z, Yan X, et al. Albumin-Bilirubin (ALBI) as an accurate and simple prognostic score for chronic hepatitis B-related liver cirrhosis. Dig Liver Dis.. 2019;51:1172–1178.CrossRef Wang J, Zhang Z, Yan X, et al. Albumin-Bilirubin (ALBI) as an accurate and simple prognostic score for chronic hepatitis B-related liver cirrhosis. Dig Liver Dis.. 2019;51:1172–1178.CrossRef
18.
go back to reference Hsieh YC, Lee KC, Wang YW, et al. Correlation and prognostic accuracy between noninvasive liver fibrosis markers and portal pressure in cirrhosis: role of ALBI score. PLoS One.. 2018;13:e0208903.CrossRef Hsieh YC, Lee KC, Wang YW, et al. Correlation and prognostic accuracy between noninvasive liver fibrosis markers and portal pressure in cirrhosis: role of ALBI score. PLoS One.. 2018;13:e0208903.CrossRef
19.
go back to reference Piano S, Romano A, Di Pascoli M, et al. Why and how to measure renal function in patients with liver disease. Liver Int.. 2017;37:116–122.CrossRef Piano S, Romano A, Di Pascoli M, et al. Why and how to measure renal function in patients with liver disease. Liver Int.. 2017;37:116–122.CrossRef
20.
go back to reference Piano S, Brocca A, Angeli P. Renal function in cirrhosis: a critical review of available tools. Semin Liver Dis.. 2018;38:230–241.CrossRef Piano S, Brocca A, Angeli P. Renal function in cirrhosis: a critical review of available tools. Semin Liver Dis.. 2018;38:230–241.CrossRef
21.
go back to reference Fede G, D’Amico G, Arvaniti V, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol.. 2012;56:810–818.CrossRef Fede G, D’Amico G, Arvaniti V, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol.. 2012;56:810–818.CrossRef
22.
go back to reference Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep.. 2012;61:1–32.PubMed Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep.. 2012;61:1–32.PubMed
23.
go back to reference Alberts M, Chen YW, Lin JH, et al. Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin. Stroke. 2019:STROKEAHA119025554. Alberts M, Chen YW, Lin JH, et al. Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin. Stroke. 2019:STROKEAHA119025554.
24.
go back to reference Tapper EB, Hao S, Lin M, et al. The quality and outcomes of care provided to patients with cirrhosis by advanced practice providers. Hepatology.. 2019;71:225–234.CrossRef Tapper EB, Hao S, Lin M, et al. The quality and outcomes of care provided to patients with cirrhosis by advanced practice providers. Hepatology.. 2019;71:225–234.CrossRef
Metadata
Title
Comparison of Seven Noninvasive Models for Predicting Decompensation and Hospitalization in Patients with Cirrhosis
Authors
Chia-Yang Hsu
Neehar D. Parikh
Teh-Ia Huo
Elliot B. Tapper
Publication date
01-12-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2021
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06763-9

Other articles of this Issue 12/2021

Digestive Diseases and Sciences 12/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.